실적분석 2026년 8월 5일

CVS Health ($CVS) Q2 2026 Earnings Analysis — Adjusted EPS Significantly Beats, Full-Year Guidance Raised

Earnings Scorecard

Revenue: $106.096 billion (+7.3% YoY, vs. $100.087 billion estimate) ✅ Beat

EPS: Adjusted $2.58 (vs. $1.85 estimate) ✅ Beat · GAAP diluted $2.31

Guidance: Raised — FY2026 adjusted EPS $7.90–$8.10 (prior $7.30–$7.50), GAAP diluted EPS $6.84–$7.04 (prior $6.24–$6.44)

Stock reaction: After-hours +2.98% ($107.53) — as of 08-05 20:47 KST

Positives

Adjusted EPS significantly beat: Q2 2026 adjusted EPS of $2.58 came in well above the $1.85 consensus.

Health Benefits margin recovery: The medical benefit ratio improved to 87.4% from 89.9% a year earlier.

Full-year guidance raised: The company lifted its FY2026 outlook for both adjusted and GAAP EPS.

Consolidated revenue rose to $106.096 billion, up 7.3% from $989.15 billion a year earlier, with growth across every business segment. Adjusted operating profit climbed 35.4% to $5.157 billion, and net income attributable to common shareholders came in at $2.979 billion (GAAP diluted EPS $2.31). This differs from total net income of $2.995 billion after accounting for noncontrolling interests and other items.

The Health Benefits segment was the key driver. Adjusted operating profit surged 85.5% YoY to $2.426 billion, helped by improvements in the government-insured business and the absence of a $471 million prior-year premium deficiency reserve related to Group Medicare Advantage. Adjusted operating profit at Pharmacy & Consumer Wellness (Health Services) and the Retail Pharmacy (Pharmacy & Consumer Wellness) segment also rose 10.0% and 10.2%, respectively, lifting results across the board.

Negatives

Membership decline: Medical membership fell to 26.0 million from 26.7 million a year earlier.

Retail pharmacy pricing and reimbursement pressure: Regulatory drug-price cuts, generic conversion, and pharmacy reimbursement pressure capped top-line growth.

Second-half cost and macro caution: The company struck a cautious tone, citing a high cost trend and the potential for macro headwinds.

The membership decline was driven mainly by the exit from the individual exchange (Individual Exchange) business in 2026, partially offset by growth in government-insured plans. Retail pharmacy revenue edged up only slightly to $33.816 billion YoY, as regulatory drug-price cuts and reimbursement pressure offset the contribution from the Rite Aid prescription file acquisition and a 4.3% increase in prescription volume.

The 97.5% jump in GAAP operating profit also reflects a one-off tailwind — the absence of an $833 million legacy legal charge booked a year earlier. Results were strong on an adjusted basis as well, but stripping out the prior-year base effect, investors will need to look at the underlying, sustainable improvement on its own.

What Management Said

Chairman and CEO David Joyner emphasized that the company continues to deliver strong results by offering technology-enabled, connected care experiences. Management said execution on the Health Benefits margin recovery plan was central to the adjusted EPS growth.

The full-year guidance raise reflects upgrades to both the Health Benefits and Retail Pharmacy segments. At the same time, management kept a "cautious view" on the back half, leaving the door open to a high medical and operating cost trend and potential macro headwinds — a signal that investors should track the durability of cost discipline rather than over-read the magnitude of the raise. Operationally, the company highlighted digital investments, including expanded access to GLP-1 therapies for weight and diabetes management and AI-enabled call-center and claims-support tools.

Market Reaction and What to Watch Next

The market appears to be pricing in the sizable adjusted EPS beat and the raised full-year guidance first. With Health Benefits margin recovery now confirmed in the numbers, the relief that the long-feared insurance profitability concern is moving in the right direction naturally tilted flows toward buyers.

That said, the membership decline and back-half cost caution make it hard to be one-sidedly optimistic. In the regular session, the close-to-close move and analyst commentary on how to reassess the size of the guidance raise and the durability of margins will be the next focal point.

Whether the medical benefit ratio improves further in Q3, or rises again on seasonal and utilization trends.

Whether Pharmacy and Care Management margins outside Health Benefits support the path to the top end of the FY adjusted EPS range ($8.10).

Tracking whether the membership mix stabilizes post-individual-exchange exit and whether government-insured growth continues to fill the revenue gap.